January 24, 2024
DUBLIN, Ireland — Ocumetra has released new updates to its mEYE Guide and mEYE Gauge software for ECPs. The revamped platform introduces a sleek design while maintaining a user-friendly interface. Notably, data entry for both mEYE Guide and mEYE Gauge has been streamlined into a single form, optimizing chair time efficiency in practice.
Among the new features is axial length analysis using either estimated or measured axial length data. The unique capability of this feature ensures that ECPs are not limited by biometry, either due to availability in practice or by the software capability of their biometer.
“Understanding the clinical context of axial length in relation to specific individuals is crucial in myopia management,” said Prof. James Loughman, CEO of Ocumetra. “By providing normative data and future adult predictions, we empower ECPs with enhanced clinical knowledge.”
The update also incorporates axial length treatment targets, facilitating improved communication regarding the need for treatment between ECPs and patients or parents.
“This latest update underscores our commitment to continuous improvement and innovation,” said Prof. Ian Flitcroft, Chief Innovation Officer at Ocumetra. “We are proud to have addressed requests from our customers and industry partners and delivered these capabilities. We stand by our aim to resolve all barriers to myopia management for ECPs in practice in order to improve eye health outcomes for children across the globe.”
To help ECPs achieve comprehensive and successful myopia care, data science company Ocumetra is committed to the development of customized, evidence-based tools including:
- Patient Communication Tools: Saving chair time and maximizing patient uptake of myopia management.
- Artificial Intelligence Tools: Increasing the understanding and use of axial length in clinical routines with or without access to biometry devices.
- Clinical Decision Support and Risk Profiling Tools: Identifying children most in need of treatment and helping ECPs demonstrate treatment benefits to parents.
- Treatment Monitoring Tools: Supporting evidence-based clinical decision making and optimizing treatment retention (coming soon).
mEYE Guide: A parent communication tool designed to increase uptake and retention of myopia management, maximizing the efficiency of ECP chair time. Through intuitive data and graphical outputs, mEYE Guide illustrates the risks of myopia and benefits of myopia management using refraction centile graphs, a vision simulator, and treatment benefit infographics. mEYE Guide powers shorter, simpler, and more effective patient and parent communication.
mEYE Gauge: An axial length estimator utilizing a machine learning algorithm to provide accurate axial length estimations using routinely captured clinical information. This tool supports the integration of axial length as an important clinical biomarker for myopia without the cost of investing in biometry devices, bringing the gold standard for myopia treatment monitoring to a broader range of clinicians. mEYE Gauge allows ECPs the opportunity to integrate axial length into their daily practice and to understand the value of axial length data for enhanced clinical decision making, thereby supporting future investment in biometry.
Ocumetra’s mEYE Guide and mEYE Gauge are available on a subscription basis. A free trial (along with terms and conditions) is available at mcp.ocumetra.com.
Alternatively, prescribers of CooperVision Myopia Management products can visit cvi.ocumetra.com to secure an exclusive offer supported by Ocumetra’s partners at Coopervision, including an extended two-month free trial and 20% discount off monthly subscription fees for the first year. This offer provides an overall 50% promotional discount on first-year access to mEYE Guide and mEYE Gauge.
